7,8-dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one | 72584-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one
• 英文别名: 7,8-Dimethoxy-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one；7,8-dimethoxy-2,3,4,5-tetrahydro-2-benzazepin-1-one
• CAS: 72584-69-1
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: DZOCZUZUPCWGRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7,8-dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one 在 potassium fluoride 、 tetraphosphorus decasulfide 、 potassium n-butoxide 、 三苯基膦 作用下， 以 甲醇 、 乙醚 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 、 苯 为溶剂， 反应 32.5h， 生成 2-Hydroxy-9,10-dimethoxy-2-((E)-4-methoxy-2-oxo-but-3-enyl)-3-oxo-2,5,6,7-tetrahydro-3H-benzo[c]pyrrolo[1,2-a]azepine-1-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis of Erythrina and Related Alkaloids Part XLIV. Total Synthesis of Homoerythrinan Alkaloids, Schelhammericine and 3-Epischelhammericine.

  摘要：

  描述了两种同红藻碱（homerythrinan alkaloids），即施尔哈默碱（schelhammericine）和3-去施尔哈默碱（3-epischelhammericine）的总合成。将一个二氧基吡咯苯并氮烯（dioxopyrrolobenzazepine）与1-甲氧基-3-三甲基硅氧基丁二烯进行光环加成，得到了线性和立体特异性的环丁烷衍生物，该衍生物通过利用TBAF诱导的1,3-阴离子重排转化为同红藻衍生物。最终产物在几步反应中转化为目标碱类。

  DOI：

  10.1248/cpb.44.500
• 作为产物：
  描述：

  3-(3,4-dimethoxyphenyl)propyl isocyanate 在 四氯化锡 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 17.0h， 生成 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-1-one
  参考文献：
  名称：

  Synthesis of Erythrina and Related Alkaloids Part XLIV. Total Synthesis of Homoerythrinan Alkaloids, Schelhammericine and 3-Epischelhammericine.

  摘要：

  描述了两种同红藻碱（homerythrinan alkaloids），即施尔哈默碱（schelhammericine）和3-去施尔哈默碱（3-epischelhammericine）的总合成。将一个二氧基吡咯苯并氮烯（dioxopyrrolobenzazepine）与1-甲氧基-3-三甲基硅氧基丁二烯进行光环加成，得到了线性和立体特异性的环丁烷衍生物，该衍生物通过利用TBAF诱导的1,3-阴离子重排转化为同红藻衍生物。最终产物在几步反应中转化为目标碱类。

  DOI：

  10.1248/cpb.44.500

文献信息

• Bronchorelaxing compounds
  申请人：Skogvall Staffan

  公开号：US20050165004A1

  公开（公告）日：2005-07-28

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR 9 , wherein R 9 is H, C 1 -C 6 alkyl; n is 1-3; B is CHR 10 , wherein R 10 is H, C 1 -C 6 alkyl; m is 1 or 2; D is O or S or optionally NR 16 , wherein R 16 is H, C 1 -C 6 alkyl or C 2 -C 6 acyl; E is CR 11 R 12 or NR 13 , wherein R 11 and R 12 are, independent of each other, H or C 1 -C 6 alkyl, R 13 is H or C 1 -C 6 alkyl; F is C 1 -C 18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

  通用式（I）的化合物及其药学上可接受的酸盐包括其中 其中A为CHR 9 ，其中R 9 为H，C 1 -C 6 烷基；n为1-3；B为CHR 10 ，其中R 10 为H，C 1 -C 6 烷基；m为1或2；D为O或S或可选地为NR 16 ，其中R 16 为H，C 1 -C 6 烷基或C 2 -C 6 酰基；E为CR 11 R 12 或NR 13 ，其中R 11 和R 12 独立地为H或C 1 -C 6 烷基，R 13 为H或C 1 -C 6 烷基；F为C 1 -C 18 烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管痉挛为特征的肺部疾病。还公开了包含该化合物的药物组合物及其制备方法。
• SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure
  作者：Marı´a F. Dalence-Guzmán、Magnus Berglund、Staffan Skogvall、Olov Sterner

  DOI：10.1016/j.bmc.2007.11.055

  日期：2008.3

  Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5 -tetrahydro-1H-2-benzazepi ne and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.
• The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capsaicin and Resiniferatoxin
  作者：Christopher S. J. Walpole、Stuart Bevan、Guenter Bovermann、Johann J. Boelsterli、Robin Breckenridge、John W. Davies、Glyn A. Hughes、Iain James、Lukas Oberer、Janet Winter、Roger Wrigglesworth

  DOI：10.1021/jm00039a006

  日期：1994.6.1

  Capsaicin and resiniferatoxin are natural products which act specifically on a subset of primary afferent sensory neurons to open a novel cation-selective ion channel in the plasma membrane. These sensory neurons are involved in nociception, and so, these agents are targets for the design of a novel class of analgesics. Although synthetic agonists at the capsaicin receptor have been described previously, competitive antagonists at this receptor would be interesting and novel pharmacological agents. Structure-activity relationships for capsaicin agonists have previously been rationalized, by ourselves and others, by dividing the capsaicin molecule into three regions-the A (aromatic ring)-, B (amide bond)-, and C (hydrophobic side chain)-regions. In this study, the effects on biological activity of conformational constraint of the A-region with respect to the B-region are discussed. Conformational constraint was achieved by the introduction of saturated ring systems of different sizes. The resulting compounds provided agonists of comparable potency to unconstrained analogues as well as a moderately potent antagonist, capsazepine. This compound is the first competitive antagonist of capsaicin and resiniferatoxin to be described and is active in various systems, in vitro and in vivo. It has recently attracted considerable interest as a tool for dissecting the mechanisms by which capsaicin analogues evoke their effects. NMR spectroscopy and X-ray crystallography experiments, as well as molecular modeling techniques, were used to study the conformational behavior of a representative constrained agonist and antagonist. The conformation of the saturated ring contraint in the two cases was found to differ markedly, dramatically affecting the relative disposition of the A-ring and B-region pharmacophores. In agonist structures, the A- and B-regions were virtually coplanar in contrast to those in the antagonist, in which they were approximately orthogonal. A rationale for agonist and antagonist activity at the capsaicin receptor is proposed, based on the consideration of these conformational differences.
• Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding σ1 and σ2 receptors
  作者：Kuo-Hsien Fan、John R. Lever、Susan Z. Lever

  DOI：10.1016/j.bmc.2011.02.006

  日期：2011.3

  5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2,3-dimethoxy-benzamide (1) is one of the most potent and selective sigma(2) receptor ligands reported to date. A series of new analogs, where the amine ring fused to the aromatic ring was varied in size (5-7) and the location of the nitrogen in this ring was modified, has been synthesized and assessed for their sigma(1)/sigma(2) binding affinity and selectivity. The binding affinity of an open-chained variant of 1 was also evaluated. Only the five-membered ring congener of 1 displayed a higher sigma(1)/sigma(2) selectivity, derived from a higher sigma(2) affinity and a lower sigma(1) affinity. Positioning the nitrogen adjacent to the aromatic ring in the five-membered and six-membered ring congeners dramatically decreased affinity for both subtypes. Thus, location of the nitrogen within a constrained ring is confirmed to be key to the exceptional sigma(2) receptor binding affinity and selectivity for this active series. (C) 2011 Elsevier Ltd. All rights reserved.
• Isobe, Kimiaki; Mohri, Kunihiko; Tokoro, Katsumi, Chemical and pharmaceutical bulletin, 1988, vol. 36, # 4, p. 1275 - 1282
  作者：Isobe, Kimiaki、Mohri, Kunihiko、Tokoro, Katsumi、Fukushima, Chie、Higuchi, Fumika、Taga, Jun-ichi

  DOI：——

  日期：——